HCM
GMAB icon

Hollencrest Capital Management’s Genmab GMAB Stock Holding History

Hollencrest Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,931
Closed -$953K – 1255
2025
Q4 		$953K Buy
+30,931
New +$964K 0.03% 159
2023
Q1 		– Sell
-560
Closed -$23.7K – 1156
2022
Q4 		$23.7K Buy
+560
New +$23.1K ﹤0.01% 580

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Hollencrest Capital Management's GMAB Position: Q1 2026 in Review

Hollencrest Capital Management sold out of Genmab (GMAB) in Q1 2026, closing a stake of 30,931 shares — an estimated $953K sold.

Hollencrest Capital Management first reported a position in GMAB in Q4 2022 and held it in 2 quarters. The position peaked at $953K in Q4 2025. 274 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Hollencrest Capital Management reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
  • Hollencrest Capital Management sold 30,931 Genmab shares in Q1 2026, an estimated $953K.
  • Hollencrest Capital Management first reported a position in Genmab in Q4 2022 and held it in 2 quarters.
  • Hollencrest Capital Management's Genmab position peaked at $953K in Q4 2025.
  • 274 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Hollencrest Capital Management's 13F filing for Q1 2026, filed 7 May 2026.